Jeffrey A. Meyerhardt, MD, considers the BEACON study in BRAF mutated metastatic colorectal cancer

preview_player
Показать описание
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, discusses the BEACON study investigating the role of encorafenib, binimetinib and cetuximab in patients with BRAF mutated metastatic colorectal cancer (mCRC)
  1. OBRoncology
Рекомендации по теме
Jeffrey A. Meyerhardt, 0:01:20

Jeffrey A. Meyerhardt, MD, considers the BEACON study in BRAF mutated metastatic colorectal cancer

Jeffrey A. Meyerhardt, 0:01:02

Jeffrey A. Meyerhardt, MD, on whether regorafenib is becoming more tolerable for mCRC patients

Jeffrey A. Meyerhardt, 0:02:56

Jeffrey A. Meyerhardt, MD, talks about the DFCI wellness study

Jeffrey A. Meyerhardt, 0:01:31

Jeffrey A. Meyerhardt, MD, explains which molecular tests help determine treatment approach

Jeffrey Meyerhardt, MD, 0:00:55

Jeffrey Meyerhardt, MD, MPH, considers the addition of vemurafenib to the NCCN guidelines for mCRC

Jeffrey A. Meyerhardt, 0:01:22

Jeffrey A. Meyerhardt, MD, talks about the DFCI wellness study

Jeffrey A. Meyerhardt, 0:01:45

Jeffrey A. Meyerhardt, MD explains integration of Stivarga and Lonserf in later lines of treatment

Jeffrey A. Meyerhardt, 0:01:35

Jeffrey A. Meyerhardt, MD, discusses how consensus molecular subtypes help with CRC treatment

Colorectal Cancer – 0:05:55

Colorectal Cancer – An Introduction, with Jeffrey A. Meyerhardt, MD, MPH

Jeffrey A. Meyerhardt, 0:01:41

Jeffrey A. Meyerhardt, MD, explains matching mutations and markers to therapies in CRC patients

Jeffrey A. Meyerhardt, 0:01:01

Jeffrey A. Meyerhardt, MD, shares thoughts on checkpoint inhibitors in adjuvant CRC

Jeffrey A. Meyerhardt, 0:02:14

Jeffrey A. Meyerhardt, MD, on managing 2nd and 3rd line mCRC patients

Jeffrey A. Meyerhardt, 0:00:58

Jeffrey A. Meyerhardt, MD explains how OS from primary site of tumor may impact treatment

Jeffrey A. Meyerhardt, 0:00:53

Jeffrey A. Meyerhardt, MD discusses the phase 3 CALGB/SWOG 80405 study

Jeffrey Meyerhardt, MD, 0:00:42

Jeffrey Meyerhardt, MD, MPH, on dose escalation of regorafenib as a result of the ReDOS study

Jeffrey A. Meyerhardt, 0:01:11

Jeffrey A. Meyerhardt, MD weighs in on the economic vs efficacy outcomes in CALGB/SWOG 80405

Jeffrey A. Meyerhardt, 0:01:43

Jeffrey A. Meyerhardt, MD, discusses outcomes of the phase 2 study in BRAF mutated CRC patients

Jeffrey A. Meyerhardt, 0:01:01

Jeffrey A. Meyerhardt, MD on PD-1 or PD-L1 treatment strategies for MSI-Stable mCRC patients

Jeffrey Meyerhardt, MD, 0:01:34

Jeffrey Meyerhardt, MD, on how immunotherapies are being studied in gastric & esophageal cancers

Jeffrey A. Meyerhardt, 0:01:50

Jeffrey A. Meyerhardt, MD, on integrating immunotherapy into treatment regimens for GI cancer

Jeffrey Meyerhardt, MD, 0:00:48

Jeffrey Meyerhardt, MD, MPH, discusses the length of adjuvant therapy for colorectal cancer patients

Three Generations of 0:03:21

Three Generations of Cancer Researchers

Jeffrey Meyerhardt, MD, 0:02:29

Jeffrey Meyerhardt, MD, regarding the optimal duration of therapy in stage III colon cancer patients

Understanding Clinical Practice 0:13:18

Understanding Clinical Practice Guidelines, with Jeffrey Meyerhardt, MD, MPH, FASCO, and Scott Ta...